STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Character Communications, solid preclinical benefits for a new COVID-19 vaccine, made by the crew of Prof. Salanti from University of Copenhagen, ExpreS2ion Biotech, its joint undertaking lover AdaptVac and the Avoid-nCoV consortium, was published. Centered on these outcomes, a clinical trial application (CTA) for a scientific Period I/II analyze for the COVID-19 vaccine has been submitted.
About the preclinical final results
Readouts from the facts display that ABNCoV2 has the prospective to be the most effective-in-class COVID-19 vaccine with a a lot more than 100-fold bigger stage of neutralizing antibodies when compared with published preclinical animal info from at present authorised COVID-19 vaccines, this sort of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The total paper is obtainable on line and can be read in this article.
About the CTA
The Clinical trial application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) centered COVID-19 vaccine was submitted to the Central Committee on Analysis Involving Human Subjects (CCMO) in the Netherlands last week. It is anticipated to be permitted underneath a COVID-19 fast-track review progress. This can be found as an additional important milestone following the November 2020 announcement of the effective GMP producing of the vaccine. ExpreS2ion expects to current preliminary clinical Phase I/IIa final results right before close of Q1 2021.
Since March 2020, Attana has been helping the staff of Prof. Ali Salanti at the University of Copenhagen in the enhancement of this COVID-19 vaccine with two of Attana’s QCM Biosensors mixed with research intelligence. As can be seen in the paper revealed, Attana’s know-how has foremost been utilised to analyze kinetic interactions in between RBD antigens and CLP-RBD to hACE2. Additionally, Attana and ExpreS2ion just lately set up a strategic partnership including a supply arrangement of proteins. In addition, Attana technology has been utilized to high-quality regulate the vaccine for the IND submission.
Attana CEO Teodor Aastrup reviews:
“I’m thrilled for our associates sake and for the future of vaccine development and would like to congratulate all get-togethers involved for achieving such enjoyable effects. I’m now wanting ahead to explore this collaboration even further and to with any luck , perform extra carefully with the two Prof. Salanti and the group at ExpreS2ion in the close to time foreseeable future.”
For a lot more information and facts, please call:
+46 () 8 674 57 00
The Board of administrators for Attana look at that the info in this press release is not very likely to have a sizeable impact on the share value but is of basic curiosity for the shareholders and hence should really be communicated.
Attana was established in 2002 with the eyesight of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Due to the fact then, Attana has created proprietary label no cost biosensors for biochemical, crude, sera, and mobile-based mostly assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and investigate providers are utilized by Big Pharma, biotech firms and tutorial institutions in the existence sciences. To learn additional about our hottest companies and items, remember to visit www.attana.se or get in touch with [email protected]
This details was introduced to you by Cision http://information.cision.com
The subsequent data files are available for down load: